Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
Identifieur interne : 000608 ( Istex/Corpus ); précédent : 000607; suivant : 000609Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
Auteurs : Emmanuelle Bondon-Guitton ; Santiago Perez-Lloret ; Haleh Bagheri ; Christine Brefel ; Olivier Rascol ; Jean-Louis MontastrucSource :
- Movement Disorders [ 0885-3185 ] ; 2011-10.
English descriptors
- KwdEn :
Abstract
Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23828
Links to Exploration step
ISTEX:14DB4B8B72EEA12B30E737B0D05908027E7AA6C7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title><author><name sortKey="Bondon Uitton, Emmanuelle" sort="Bondon Uitton, Emmanuelle" uniqKey="Bondon Uitton E" first="Emmanuelle" last="Bondon-Guitton">Emmanuelle Bondon-Guitton</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23828</idno><idno type="url">https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000608</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title><author><name sortKey="Bondon Uitton, Emmanuelle" sort="Bondon Uitton, Emmanuelle" uniqKey="Bondon Uitton E" first="Emmanuelle" last="Bondon-Guitton">Emmanuelle Bondon-Guitton</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-10">2011-10</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2226">2226</biblScope><biblScope unit="page" to="2231">2231</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</idno><idno type="DOI">10.1002/mds.23828</idno><idno type="ArticleID">MDS23828</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>adverse drug reactions</term><term>antipsychotics</term><term>calcium channel blockers</term><term>dopaminergic antagonists</term><term>drug safety</term><term>neuroleptics</term><term>parkinsonism</term><term>pharmacovigilance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Emmanuelle Bondon‐Guitton PharmD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string></affiliations></json:item><json:item><name>Santiago Perez‐Lloret MD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string><json:string>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</json:string></affiliations></json:item><json:item><name>Haleh Bagheri PharmD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Brefel MD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string><json:string>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</json:string></affiliations></json:item><json:item><name>Jean‐Louis Montastruc MD, PhD</name><affiliations><json:string>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroleptics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antipsychotics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopaminergic antagonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>calcium channel blockers</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>adverse drug reactions</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pharmacovigilance</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug safety</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>7.466</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>2022</abstractCharCount><pdfWordCount>3966</pdfWordCount><pdfCharCount>27615</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>272</abstractWordCount></qualityIndicators><title>Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title><genre><json:string>Serial article</json:string></genre><host><volume>26</volume><pages><total>6</total><last>2231</last><first>2226</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23828</json:string></doi><id>14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Prof. Rascol has received consulting fees from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Schering, Solvay, Teva Neuroscience, XenoPort, Oxford Biomedica, Movement Disorders Society, Lundbeck, Servier, and UCB and scientific grants from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Solvay, Teva Neuroscience, and Lundbeck. Dr. Brefel has received consulting fees from Boehringer Ingelheim, GlaxoSmithKline, and Medtronic.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title><author><persName><forename type="first">Emmanuelle</forename><surname>Bondon‐Guitton</surname><roleName type="degree">PharmD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31000 Toulouse, France</p></note><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation></author><author><persName><forename type="first">Santiago</forename><surname>Perez‐Lloret</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</affiliation></author><author><persName><forename type="first">Haleh</forename><surname>Bagheri</surname><roleName type="degree">PharmD, PhD</roleName></persName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Brefel</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</affiliation></author><author><persName><forename type="first">Jean‐Louis</forename><surname>Montastruc</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-10"></date><biblScope unit="vol">26</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2226">2226</biblScope><biblScope unit="page" to="2231">2231</biblScope></imprint></monogr><idno type="istex">14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</idno><idno type="DOI">10.1002/mds.23828</idno><idno type="ArticleID">MDS23828</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>parkinsonism</term></item><item><term>neuroleptics</term></item><item><term>antipsychotics</term></item><item><term>dopaminergic antagonists</term></item><item><term>calcium channel blockers</term></item><item><term>adverse drug reactions</term></item><item><term>pharmacovigilance</term></item><item><term>drug safety</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-10-27">Received</change><change when="2011-05-12">Registration</change><change when="2011-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/14DB4B8B72EEA12B30E737B0D05908027E7AA6C7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v26.12</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2011-10">October 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="180" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23828</doi><idGroup><id type="unit" value="MDS23828"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-10-27"></event><event type="manuscriptRevised" date="2011-05-06"></event><event type="manuscriptAccepted" date="2011-05-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-04"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-06-14"></event><event type="publishedOnlineFinalForm" date="2011-10-21"></event><event type="firstOnline" date="2011-06-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2226</numbering><numbering type="pageLast">2231</numbering></numberingGroup><correspondenceTo>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31000 Toulouse, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23828.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="39"></count><count type="wordTotal" number="4748"></count></countGroup><titleGroup><title type="main" xml:lang="en">Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France<link href="#fn1"></link><link href="#fn3"></link></title><title type="short" xml:lang="en">Drug‐Induced Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Emmanuelle</givenNames><familyName>Bondon‐Guitton</familyName><degrees>PharmD, PhD</degrees></personName><contactDetails><email>guitton@cict.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Santiago</givenNames><familyName>Perez‐Lloret</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Haleh</givenNames><familyName>Bagheri</familyName><degrees>PharmD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christine</givenNames><familyName>Brefel</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jean‐Louis</givenNames><familyName>Montastruc</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">parkinsonism</keyword><keyword xml:id="kwd2">neuroleptics</keyword><keyword xml:id="kwd3">antipsychotics</keyword><keyword xml:id="kwd4">dopaminergic antagonists</keyword><keyword xml:id="kwd5">calcium channel blockers</keyword><keyword xml:id="kwd6">adverse drug reactions</keyword><keyword xml:id="kwd7">pharmacovigilance</keyword><keyword xml:id="kwd8">drug safety</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures</b>: Prof. Rascol has received consulting fees from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Schering, Solvay, Teva Neuroscience, XenoPort, Oxford Biomedica, <i>Movement</i> Disorders Society, Lundbeck, Servier, and UCB and scientific grants from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Solvay, Teva Neuroscience, and Lundbeck. Dr. Brefel has received consulting fees from Boehringer Ingelheim, GlaxoSmithKline, and Medtronic.</p></note><note xml:id="fn3"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Drug‐Induced Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France</title></titleInfo><name type="personal"><namePart type="given">Emmanuelle</namePart><namePart type="family">Bondon‐Guitton</namePart><namePart type="termsOfAddress">PharmD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><description>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31000 Toulouse, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Santiago</namePart><namePart type="family">Perez‐Lloret</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Haleh</namePart><namePart type="family">Bagheri</namePart><namePart type="termsOfAddress">PharmD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><affiliation>INSERM Centre d'Investigation Clinique CIC 9203, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Louis</namePart><namePart type="family">Montastruc</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine de l'Université de Toulouse, Toulouse and Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de PharmacoVigilance, de PharmacoEpidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-10</dateIssued><dateCaptured encoding="w3cdtf">2010-10-27</dateCaptured><dateValid encoding="w3cdtf">2011-05-12</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="references">39</extent><extent unit="words">4748</extent></physicalDescription><abstract lang="en">Besides antipsychotics, several drugs can induce parkinsonism. We review spontaneous notifications of drug‐induced or ‐worsened parkinsonism to a French regional pharmacovigilance center between 1993 and 2009. During these 17 years, 20,855 adverse drug reactions have been reported, including 155 (0.7%) cases of drug‐induced or ‐worsened parkinsonism. Most of the notifications have involved aged patients (48% between 60 and 79 years) and females (60%). “Seriousness” was found in 43.9% of cases. Worsening of parkinsonism occurred in 28 patients suffering from idiopathic Parkinson's disease. Sixty‐nine percent of drug‐induced or ‐worsened parkinsonism cases were observed during the first 3 months after introduction of the “suspect” drug (involving mainly central dopaminergic antagonists). A second peak (20%) was found 12 months after drug introduction (mainly caused by calcium channel blockers). The most frequently reported parkinsonian symptom was rigidity (78.7%). The three cardinal symptoms were found in 37.4% of notifications. Evolution was favorable (after partial or complete withdrawal of suspect drug[s]) in 88.7% of cases. Among the 261 suspect drugs, most involved central dopaminergic antagonists (49%), followed by antidepressants (8%), calcium channel blockers (5%), peripheral dopaminergic antagonists (5%), and H1 antihistamines (5%). Cases with lithium, valproic acid, amiodarone, anticholinesterases, or trimetazidine were also found. Three notifications were the result of pharmacokinetic interactions. We found that drug‐induced or ‐worsened parkinsonism is an often “serious,” but reversible, adverse drug reaction. It occurred more frequently between 60 and 79 years. Rigidity was the most frequently reported symptom. Approximately 50% of drug‐induced or ‐worsened parkinsonism cases spontaneously reported were related to drugs other than antipsychotics. Drug‐induced or ‐worsened parkinsonism can also be explained by pharmacokinetic drug interactions. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Prof. Rascol has received consulting fees from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Schering, Solvay, Teva Neuroscience, XenoPort, Oxford Biomedica, Movement Disorders Society, Lundbeck, Servier, and UCB and scientific grants from Boehringer Ingelheim, Eisai, GlaxoSmithKline, Novartis, Solvay, Teva Neuroscience, and Lundbeck. Dr. Brefel has received consulting fees from Boehringer Ingelheim, GlaxoSmithKline, and Medtronic.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>parkinsonism</topic><topic>neuroleptics</topic><topic>antipsychotics</topic><topic>dopaminergic antagonists</topic><topic>calcium channel blockers</topic><topic>adverse drug reactions</topic><topic>pharmacovigilance</topic><topic>drug safety</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>2226</start><end>2231</end><total>6</total></extent></part></relatedItem><identifier type="istex">14DB4B8B72EEA12B30E737B0D05908027E7AA6C7</identifier><identifier type="DOI">10.1002/mds.23828</identifier><identifier type="ArticleID">MDS23828</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000608 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000608 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:14DB4B8B72EEA12B30E737B0D05908027E7AA6C7
|texte= Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
}}
| This area was generated with Dilib version V0.6.23. |  |